Reportedly, Amgen’s (AMGN) and AstraZeneca’s (AZN) experimental drugs have proven to reduce asthma attacks in patients with uncontrolled and severe forms of the respiratory condition in a large study.
The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study with 1000 patients already receiving proper standard care. The drug also worked well in a subgroup of volunteers with low levels of eosinophils, a type of white blood cell.
Tezepelumab further improved lung function in patients helped control asthma better and reduced the risk of hospitalizations or emergency visits by 79%.
Tezepelumab blocks TSLP, a type of immune protein found in the linings of the lungs. If approved, the biologic drug will compete with AstraZeneca’s Regeneron’s Dupixent and Fasenra.
“Alongside Fasenra, we think that having two really strong complementary, robust biologics in this space will actually expand use in eligible patients,” stated Richard Marshall, global head of late respiratory and immunology at AstraZeneca.
AstraZeneca’s Fasenra, with almost $1 billion in sales last year, is a strong prospect in the market to treat severe eosinophilic asthma, but with Tezepelumab the company could offer to treat non-eosinophilic patients.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
